این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۱، شماره ۱، صفحات ۴۳-۴۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients?
چکیده انگلیسی مقاله Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p< 0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusions: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+.
کلیدواژه‌های انگلیسی مقاله FISH,Hormone receptors,DFS,Trastuzumab
نویسندگان مقاله مهرداد پاینده | mehrdad payandeh
department of hematology and medical oncology, kermanshah university of medical sciences, kermanshah, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمانشاه (Kermanshah university of medical sciences)

مسعود صادقی | masoud sadeghi
students research committee, kermanshah university of medical sciences, kermanshah, iran medical biology research center, kermanshah university of medical sciences, kermanshah, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمانشاه (Kermanshah university of medical sciences)

ادریس صادقی | edris sadeghi
students research committee, kermanshah university of medical sciences, kermanshah, iran medical biology research center, kermanshah university of medical sciences, kermanshah, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمانشاه (Kermanshah university of medical sciences)

علیرضا جانبخش | alireza janbakhsh
department of infectious diseases and tropical medicine, kermanshah university of medical sciences, kermanshah, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمانشاه (Kermanshah university of medical sciences)

نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/534
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/78/article-78-350014.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات